Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amphetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.73 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | CPA3 | P15088 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levamfetamine SCHEMBL122964 | 1.00 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Dextroamphetamine SCHEMBL11760798 | 0.93 | TAAR1 (0.68) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL1237847 | 0.93 | TAAR1 (0.68) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL2323193 | 0.89 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL579073 | 0.89 | TAAR1 (0.73) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL29102142 | 0.88 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL8589685 | 0.88 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL29102157 | 0.88 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL27293366 | 0.88 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 | |
| Amphetamine SCHEMBL157108 | 0.88 | TAAR1 (0.79) | TAAR1SLC6A2SLC6A4MAOASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049722-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2025-02-13 | — | — | US | disclosed |
| EP-3261625-B1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20230121531-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20200146991-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20180185290-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2018-07-05 | — | — | US | disclosed |
| EP-3261625-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138440-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160250148-A1 | TRIPULSE RELEASE STIMULANT FORMULATIONS | Cingulate Therapeutics LLC (US) | 2016-09-01 | — | — | US | disclosed |
| US-5760044-A | Method for treating cocaine and amphetamine dependency | ALBANY MOLECULAR RESEARCH, INC. | 1998-06-02 | — | — | US | disclosed |
| WO-1997042950-A1 | METHOD FOR TREATING COCAINE AND AMPHETAMINE DEPENDENCY | ALBANY MOLECULAR RESEARCH, INC. (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |